» Articles » PMID: 15224285

Screening for Pancreatic Neoplasia in High-risk Individuals: an EUS-based Approach

Abstract

Background & Aims: Relatives of patients with pancreatic cancer and persons with certain inherited syndromes are at increased risk for developing pancreatic cancer. We prospectively evaluated the feasibility of screening for pancreatic neoplasia in high-risk individuals.

Methods: Individuals from familial pancreatic cancer kindreds and a patient with Peutz-Jeghers syndrome underwent screening endoscopic ultrasound (EUS). If the EUS was abnormal, EUS-guided fine-needle aspiration, endoscopic retrograde cholangiopancreatography (ERCP), and spiral computed tomography (CT) were performed. Patients with abnormalities suggesting neoplasia had surgery.

Results: Thirty-eight patients were studied; 31 (mean age, 58 yr; 42% men) from kindreds with > or =3 affected with pancreatic cancer; 6 from kindreds with 2 affected relatives, 1 was a patient with Peutz-Jeghers syndrome. None had symptoms referable to the pancreas or suggestive of malignancy. Six pancreatic masses were found by EUS: 1 invasive ductal adenocarcinoma, 1 benign intraductal papillary mucinous neoplasm, 2 serous cystadenomas, and 2 nonneoplastic masses. Hence, the diagnostic yield for detecting clinically significant pancreatic neoplasms was 5.3% (2 of 38). The 1 patient with pancreatic cancer was treated and still is alive and disease-free >5 years after surgery. EUS changes similar to those associated with chronic pancreatitis were found, which were more common in patients with a history of regular alcohol intake (P = 0.02), but also occurred in patients who did not consume alcohol. Screening also led to a new diagnosis and treatment of symptomatic upper-gastrointestinal conditions in 18.4% of patients.

Conclusions: EUS-based screening of asymptomatic high-risk individuals can detect prevalent resectable pancreatic neoplasia but false-positive diagnoses also occur.

Citing Articles

Pancreatic cancer: Future challenges and new perspectives for an early diagnosis.

Cocca S, Pontillo G, Lupo M, Lieto R, Marocchi M, Marsico M World J Clin Oncol. 2025; 16(2):97248.

PMID: 39995556 PMC: 11686566. DOI: 10.5306/wjco.v16.i2.97248.


Clinical Perspectives on the Histomolecular Features of the Pancreatic Precursor Lesions: A Narrative Review.

Kazemi-Harikandei S, Karimi A, Tavangar S Middle East J Dig Dis. 2024; 16(3):136-146.

PMID: 39386334 PMC: 11459284. DOI: 10.34172/mejdd.2024.387.


Twenty-five years of surveillance for familial and hereditary pancreatic ductal adenocarcinoma: Historical perspectives and introduction to the special issue.

Vasen H, Canto M, Goggins M Fam Cancer. 2024; 23(3):209-215.

PMID: 38844715 PMC: 11255030. DOI: 10.1007/s10689-024-00404-0.


The role of biomarkers in the early detection of pancreatic cancer.

Goggins M Fam Cancer. 2024; 23(3):309-322.

PMID: 38662265 PMC: 11309746. DOI: 10.1007/s10689-024-00381-4.


Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer.

Bogdanski A, van Hooft J, Boekestijn B, Bonsing B, Wasser M, Klatte D Fam Cancer. 2024; 23(3):323-339.

PMID: 38619782 PMC: 11255004. DOI: 10.1007/s10689-024-00368-1.